Working… Menu
Trial record 16 of 61 for:    "Lung Disease" | "Iloprost"

Inhaled Iloprost for the Treatment of Persistent Pulmonary Hypertension in the Term and Near Term Infants.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00409526
Recruitment Status : Terminated (Sub-Investigator left U of C)
First Posted : December 11, 2006
Last Update Posted : June 2, 2014
Information provided by (Responsible Party):
University of Chicago

Brief Summary:
Inhaled Iloprost will be administered to near term infants with Persistent Pulmonary Hypertension of the Newborn in two different doses in order to test safety and efficacy in reducing pulmonary artery pressure.

Condition or disease Intervention/treatment Phase
Pulmonary Hypertension Drug: Inhaled Iloprost Phase 4

Detailed Description:
Infants eligible for the study will be divided into two arms according to oxygenation index: Infants in arm A (OI <20) will receive nebulized Iloprost in a lower dose (50 ng/kg/min) for one hour, and a higher dose (100 ng/kg/min) for another hour. Infants in arm B (OI>20) will receive NO, and in addition will receive nebulized Iloprost in a lower dose for one hour and a higher dose for another hour.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Study: The Effect of Inhaled Iloprost on Oxygenation in Term and Near Term Infants With Pulmonary Hypertension. Testing Two Doses.
Study Start Date : December 2006
Actual Primary Completion Date : December 2007
Actual Study Completion Date : December 2007

Resource links provided by the National Library of Medicine

Drug Information available for: Iloprost

Intervention Details:
  • Drug: Inhaled Iloprost
    50 micrograms for one hour followed by 100 micrograms for one hour
    Other Name: Ventavis

Primary Outcome Measures :
  1. Oxygenation index and PaO2 after treatment with inhaled Iloprost. [ Time Frame: three hours ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 7 Days   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Near-term infants (>34 gestational age) with evidence of persistent pulmonary hypertension and severe hypoxia(PaO2<100 mmHg with mechanical ventilation with FiO2=100%).

Exclusion Criteria:

  • Major congenital malformation
  • Congenital diaphragmatic hernia
  • Structural cardiac anomalies
  • Hydrops fetalis
  • Pulmonary hemorrhage
  • Severe perinatal depression
  • Patients on high frequency oscillation ventilator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00409526

Layout table for location information
United States, Illinois
Comer Children's Hospital, The University of Chicago Hospitals
Chicago, Illinois, United States, 60637
Shaare Zedek Medical Center
Jerusalem, Israel, 91031
Sponsors and Collaborators
University of Chicago
Layout table for investigator information
Principal Investigator: Michael D Schreiber, MD University of Chicago

Layout table for additonal information
Responsible Party: University of Chicago Identifier: NCT00409526     History of Changes
Other Study ID Numbers: 14479B
First Posted: December 11, 2006    Key Record Dates
Last Update Posted: June 2, 2014
Last Verified: May 2014
Keywords provided by University of Chicago:
Pulmonary Hypertension
Persistent Pulmonary Hypertension of the Newborn
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension, Pulmonary
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Platelet Aggregation Inhibitors
Vasodilator Agents